Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
117.53
+0.06 (+0.05%)
Streaming Delayed Price
Updated: 12:08 PM EST, Feb 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Glaukos Corporation Common Stock
< Previous
1
2
3
4
Next >
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
January 28, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
January 20, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
January 13, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
December 16, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
November 03, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Third Quarter 2025 Financial Results
October 29, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces FDA Approval of Epioxa™
October 20, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting
October 14, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29
October 08, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama
September 25, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Wells Fargo Healthcare Conference
August 13, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Second Quarter 2025 Financial Results
July 30, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
July 09, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
June 25, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
June 25, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
May 13, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces First Quarter 2025 Financial Results
April 30, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 23, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces the Release of its 2024 Sustainability Report
April 16, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
April 09, 2025
From
Glaukos Corporation
Via
Business Wire
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution
March 11, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
February 24, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
February 20, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
January 23, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
January 14, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
December 23, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 17, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
November 08, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Third Quarter 2024 Financial Results
November 04, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
October 16, 2024
From
Glaukos Corporation
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
